PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
about
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisAssessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).Lack of Major Histocompatibility Complex Class I Upregulation and Restrictive Infection by JC Virus Hamper Detection of Neurons by T Lymphocytes in the Central Nervous System.Myeloid cells as target of fingolimod action in multiple sclerosis.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.Neurological safety of fingolimod: An updated reviewLong-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.
P2860
Q26765300-2D96ED36-1F17-47D1-B343-AE1C462A9B1CQ26771635-9F4B9788-DDF4-4E3F-A2EB-C8C128B3CF15Q35671182-8DE29E84-00FF-4704-88A3-BAA88F1ED533Q35864067-C2915CFF-D04D-4887-B527-9500053BB100Q36255283-E7BDE63C-44A0-4577-898F-10D54F1BB417Q36352813-71EF5C26-2532-41FB-AD7A-8E4C736A58C0Q37475542-800971FD-6657-4FEC-BF94-EA217061F540Q40090879-C046C6A8-B7EA-4311-A965-66D672122952Q41553443-0EED4EEA-ECFC-44C2-BFA9-16859F070701Q49164654-50E3600F-65DB-46FA-9D13-FED1BCB56825Q49884884-BD071EE4-395D-4E0A-84CD-4E858FEEDAB6Q51218322-9A40EF8A-4B07-43A2-A431-ACD69034BCBAQ52677983-48F0F6E3-83B9-48C7-9BBE-D51B82490CDC
P2860
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@ast
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@en
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@nl
type
label
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@ast
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@en
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@nl
prefLabel
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@ast
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@en
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@nl
P2093
P2860
P356
P1476
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
@en
P2093
A E L van Golde
A Vennegoor
J Killestein
M L B Wijlens
M P Wattjes
R L J H Bourez
P2860
P304
P356
10.1155/2014/307872
P577
2014-11-23T00:00:00Z